Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00707473|
Recruitment Status : Recruiting
First Posted : June 30, 2008
Last Update Posted : August 28, 2017
|Condition or disease||Intervention/treatment||Phase|
|Paranasal Sinus Neoplasms Squamous Cell Carcinoma||Drug: Docetaxel Drug: 5-Fluorouracil Drug: Cisplatin||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||45 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses|
|Actual Study Start Date :||June 2008|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||June 2019|
Experimental: Docetaxel, Cisplatin, and 5-Fluorouracil
Docetaxel 75 mg/m^2 IV on day 1 of each cycle. Cisplatin 75 mg/m^2 IV over 30-120 minutes on day 1 of each cycle. 5-Fluorouracil 750 mg/m^2 continuous infusion on days 1 through 4 of each cycle.
75 mg/m^2 IV on day 1 of each cycle.
Other Name: Taxotere
750 mg/m^2 continuous infusion on days 1 through 4 of each cycle.
75 mg/m^2 IV over 30-120 minutes on day 1 of each cycle.
- Number of Patients with Complete + Partial Response [ Time Frame: Response assessment after two 3 week cycles, then every 6 months for minimally 2 years ]Clinical/radiographic complete and partial responses after induction chemotherapy with docetaxel, cisplatin and fluorouracil (TPF) where Complete Response (CR): Disappearance of clinical and radiological evidence of tumor; Partial Response (PR): 50% or > decrease in overall sum of products of diameters of all target lesions in reference to baseline sum. PR defined as a 30% or > reduction in dimension target lesions; Stable Disease (SD): Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR; Progressive Disease (PD): 25% or > increase in overall sum products of diameters of all target lesions reference smallest sum recorded at or following baseline. PD is defined as a 20% or > increase in dimension of target lesions. Tumors measurable by only one dimension assessed by Response Evaluation Criteria In Solid Tumors (RECIST).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00707473
|Contact: Ehab Y. Hanna, MD||713-745-2672|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Ehab Y. Hanna, MD||M.D. Anderson Cancer Center|